This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
このページの翻訳は実験的なもので、現在 開発中です。お待ちしております！
Aceragen 将来の成長
Future 基準チェック /06
We currently don't have sufficient analyst coverage to forecast growth and revenue for Aceragen.
主要情報
n/a
収益成長率
85.2%
EPS成長率
| Biotechs 収益成長 | 24.1% |
| 収益成長率 | -161.8% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 01 Mar 2023 |
今後の成長に関する最新情報
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2024 | N/A | -63 | N/A | N/A | 1 |
| 12/31/2023 | N/A | N/A | N/A | N/A | 1 |
| 3/31/2023 | 7 | -41 | -30 | -30 | N/A |
| 12/31/2022 | 5 | -23 | -24 | -24 | N/A |
| 9/30/2022 | 0 | -16 | -15 | -15 | N/A |
| 6/30/2022 | N/A | -18 | -17 | -17 | N/A |
| 3/31/2022 | N/A | -20 | -20 | -20 | N/A |
| 12/31/2021 | N/A | 97 | -25 | -25 | N/A |
| 9/30/2021 | N/A | 24 | -28 | -28 | N/A |
| 6/30/2021 | N/A | 9 | -31 | -31 | N/A |
| 3/31/2021 | N/A | -8 | -33 | -33 | N/A |
| 12/31/2020 | N/A | -113 | -34 | -34 | N/A |
| 9/30/2020 | N/A | -87 | -37 | -37 | N/A |
| 6/30/2020 | N/A | -78 | -40 | -40 | N/A |
| 3/31/2020 | 1 | -65 | -42 | -42 | N/A |
| 12/31/2019 | 1 | -85 | -45 | -44 | N/A |
| 9/30/2019 | 2 | -45 | -46 | -46 | N/A |
| 6/30/2019 | 2 | -46 | -47 | -47 | N/A |
| 3/31/2019 | 0 | -51 | -51 | -51 | N/A |
| 12/31/2018 | 1 | -60 | -52 | -52 | N/A |
| 9/30/2018 | 1 | -63 | -52 | -52 | N/A |
| 6/30/2018 | 1 | -66 | -52 | -52 | N/A |
| 3/31/2018 | 1 | -71 | -53 | -52 | N/A |
| 12/31/2017 | 1 | -66 | -55 | -55 | N/A |
| 9/30/2017 | 16 | -50 | -39 | -39 | N/A |
| 6/30/2017 | 16 | -49 | -38 | -38 | N/A |
| 3/31/2017 | 16 | -41 | -33 | -33 | N/A |
| 12/31/2016 | 16 | -38 | N/A | -28 | N/A |
| 9/30/2016 | 1 | -51 | N/A | -42 | N/A |
| 6/30/2016 | 1 | -50 | N/A | -43 | N/A |
| 3/31/2016 | 1 | -49 | N/A | -43 | N/A |
| 12/31/2015 | 0 | -49 | N/A | -43 | N/A |
| 9/30/2015 | 0 | -49 | N/A | -44 | N/A |
| 6/30/2015 | 0 | -47 | N/A | -40 | N/A |
| 3/31/2015 | 0 | -42 | N/A | -36 | N/A |
| 12/31/2014 | 0 | -39 | N/A | -31 | N/A |
| 9/30/2014 | 0 | -34 | N/A | -26 | N/A |
| 6/30/2014 | 0 | -29 | N/A | -23 | N/A |
| 3/31/2014 | 0 | -26 | N/A | -21 | N/A |
| 12/31/2013 | 0 | -21 | N/A | -17 | N/A |
| 9/30/2013 | 0 | -21 | N/A | -17 | N/A |
| 6/30/2013 | 0 | -21 | N/A | -17 | N/A |
| 3/31/2013 | 0 | -19 | N/A | -18 | N/A |
| 12/31/2012 | 0 | -22 | N/A | -20 | N/A |
| 9/30/2012 | 0 | -26 | N/A | -19 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: Insufficient data to determine if ACGN's forecast earnings growth is above the savings rate (2.2%).
収益対市場: Insufficient data to determine if ACGN's earnings are forecast to grow faster than the US market
高成長収益: Insufficient data to determine if ACGN's earnings are expected to grow significantly over the next 3 years.
収益対市場: ACGN is forecast to have no revenue next year.
高い収益成長: ACGN is forecast to have no revenue next year.
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: Insufficient data to determine if ACGN's Return on Equity is forecast to be high in 3 years time